BRIEF-Astrazeneca announced new results data evaluating cost-effectiveness of synagis
March 28, 2017 at 09:45 AM EDT
* Astrazeneca - announced new results data evaluating cost-effectiveness of synagis for respiratory syncytial virus in preterm infants 29-34 weeks gestational age